Jemperli
Generic name: Dostarlimab-gxly
Dosage form: injection
Drug class:
Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
Usage of Jemperli
Jemperli is a prescription medicine used for the treatment of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer, and dMMR solid tumors.
Jemperli belongs to the class of drugs called programmed death receptor-1 (PD-1)–blocking antibodies. In healthy T-cells, PD-1 acts as a brake that prevents the cells from creating an out-of-control immune response, but in tumors, PD-1 can make T-cells iNACtive preventing them from killing cancer cells.
Jemperli works in the treatment of dMMR/MSI-H endometrial cancer and dMMR solid tumors by binding to the PD-1 receptor on T-cells to block the interaction with the PD-1 ligands PD-L1 and PD-L2, allowing the T-cells to activate and to attack and kill the cancer cells.
Jemperli side effects
Get emergency medical help if you have signs of an allergic Reaction to Jemperli (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Some side effects may occur during the injection. Tell your caregiver if you feel light-headed, chilled or feverish, itchy, or short of breath.
Jemperli strengthens your immune system to help it attack cancer cells, but it may also attack healthy cells and you could develop serious or fatal side effects. See Important information.
Common Jemperli side effects when given with Carboplatin and Paclitaxel in people with dMMR/MSI-H endometrial cancer include:
Common Jemperli side effects when used alone in people with dMMR solid tumors (including endometrial cancer) when used alone include:
This is not a complete list of side effects of Jemperli and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Jemperli
Before you receive Jemperli, tell your healthcare provider if you have any medical conditions, including if you:
Pregnancy
Tell your healthcare provider if you are pregnant or plan to become pregnant. Jemperli can harm your unborn baby. Females who are able to become pregnant:
Breastfeeding
Tell your healthcare provider are breastfeeding or plan to breastfeed. It is not known if Jemperli passes into your breast milk.
Relate drugs
- Atezolizumab
- Avelumab
- Bavencio
- Cemiplimab
- Cemiplimab-rwlc
- Dostarlimab
- Dostarlimab-gxly
- Durvalumab
- Imfinzi
- Jemperli
- Keytruda
- Libtayo
- Nivolumab
- Opdivo
- Pembrolizumab
- Retifanlimab
- Retifanlimab-dlwr
- Tecentriq
- Zynyz
How to use Jemperli
Usual Adult Dose for Endometrial Carcinoma:
Jemperli in combination with carboplatin and paclitaxel, for dMMR or MSI-H primary advanced or recurrent endometrial cancer: - 500 mg IV over 30 minutes every 3 weeks for 6 doses followed by 1,000 mg monotherapy every 6 weeks.
Jemperli as a single-agent, for dMMR recurrent or advanced endometrial cancer:
- 500 mg IV over 30 minutes every 3 weeks for 4 doses followed by 1,000 mg every 6 weeks.
Uses: - in combination with carboplatin and paclitaxel, followed by monotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H). - as a single agent for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinumcontaining regimen in any setting and are not candidates for curative surgery or radiation.
Usual Adult Dose for Solid Tumors:
Jemperli as a single-agent, for dMMR recurrent or advanced solid tumors:
- 500 mg IV over 30 minutes every 3 weeks for 4 doses followed by 1,000 mg every 6 weeks.
Use: - as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a cOnfirmatory trial(s).
Warnings
Jemperli can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment with Jemperli has ended.
Call or see your healthcare provider right away if you develop any symptoms of the following problems or if these symptoms get worse:
Lung problems (pneumonitis). Symptoms of pneumonitis may include:
Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include:
Liver problems, including hepatitis. Signs and symptoms of liver problems may include:
Hormone gland problems (especially the adrenal glands, pituitary, thyroid, and pancreas). Signs and symptoms that your hormone glands are not working properly may include:
Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include:
Skin problems. Signs of skin problems may include:
Problems in other organs and tissues. These are not all of the signs and symptoms of immune system problems. Call or see your healthcare provider right away for any new or worse signs or symptoms. Signs and symptoms of these problems may include:
Infusion reactions that can sometimes be severe and life-threatening. Signs and symptoms of infusion reactions may include:
Rejection of a transplanted organ. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, Depending on the type of organ transplant that you have HAD.
Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with Jemperli. Your healthcare provider will monitor you for the following signs and symptoms: skin rash, liver inflammation, stomach area (abdominal) pain, and diarrhea. Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during treatment. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment, if you have severe side effects.
What other drugs will affect Jemperli
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions